<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683109</url>
  </required_header>
  <id_info>
    <org_study_id>1237.49</org_study_id>
    <secondary_id>2015-003879-29</secondary_id>
    <nct_id>NCT02683109</nct_id>
  </id_info>
  <brief_title>Fixed Dose Combination Versus Free Combination of Tiotropium and Olodaterol in COPD</brief_title>
  <official_title>A 4-week, Randomised, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Tiotropium + Olodaterol Fixed Dose Combination (5/5 µg) Delivered by the Respimat® Inhaler Versus the Free Combination of Tiotropium 5 µg and Olodaterol 5 µg Delivered by Separate Respimat® Inhalers in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a 4-week, multicenter, randomized, double-blind, parallel group and active controlled
      study.

      Patients will be randomized (1 to 1 ratio) to a 4-week double-blind treatment period of
      either FDC (fixed-dose combination) of tiotropium + olodaterol (5/5 µg) plus placebo or the
      free combination of tiotropium 5 µg and olodaterol 5 µg; all administered via the Respimat®
      inhaler. The purpose is to show non-inferiority between the FDC and the free combination of
      tiotropium and olodaterol in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 8, 2016</start_date>
  <completion_date type="Actual">January 30, 2017</completion_date>
  <primary_completion_date type="Actual">January 9, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Trough Forced Expiratory Volume in 1 Second (FEV1) (in Liter) After 28 Days of Treatment</measure>
    <time_frame>Day 29</time_frame>
    <description>This outcome measure presents FEV1 after 28 days of treatment (measurement on Day 29). Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), and was measured at 24 hours (+/- 10 minutes) after trial medication administration at Visit 5.
The FEV1 measurement at Visit 4, which was 24 hours after the last open-label run-in treatment intake and 15 minutes before the first double-blind study drug intake was the baseline measurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough Forced Vital Capacity (FVC) (in Liter) After 28 Days of Treatment</measure>
    <time_frame>Day 29</time_frame>
    <description>This outcome measure presents trough FVC after 28 days of treatment (measurement on Day 29).
The FVC measurement at Visit 4, which was 24 hours after the last open-label run-in treatment intake and 15 minutes before the first double-blind study drug intake was the baseline measurement for FVC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Obstructive Pulmonary Disease (COPD) Assessment Test™ (CAT) Score on Day 28</measure>
    <time_frame>Day 28</time_frame>
    <description>This outcome measure presents COPD assessment test score on Day 28. The COPD Assessment Test™ is a short 8-item questionnaire for assessment and monitoring of COPD health status in routine practice. Its scale is 0-40 (high score = poor health).
The CAT measurement on Visit 4 prior to the first dose of double-blind study drug was the baseline for CAT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>FDC of tiotropium + olodaterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed Dose Combination of tiotropium + olodaterol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Free combination tiotropium + olodaterol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDC of tiotropium + olodaterol</intervention_name>
    <description>Fixed Dose Combination of tiotropium + olodaterol</description>
    <arm_group_label>FDC of tiotropium + olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>FDC of tiotropium + olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
    <arm_group_label>Free combination tiotropium + olodaterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olodaterol</intervention_name>
    <arm_group_label>Free combination tiotropium + olodaterol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female patients.

          -  Patients 40 years of age or older.

          -  Patients with a smoking history &gt; 10 pack years.

          -  Diagnostic of COPD with Post-bronchodilator FEV1 (Forced Expiratory Volume in one
             second) &gt;= 30% and &lt;80% of predicted normal and Post-bronchodilator FEV1/FVC (Forced
             Vital Capacity) &lt;70% at screening.

          -  Symptomatic patients with CAT (COPD Assessment Test TM) score &gt;= 10 at screening.

          -  Further inclusion criteria apply.

        Exclusion criteria:

          -  COPD exacerbation or symptoms of lower respiratory tract infection within 6 weeks
             prior to screening.

          -  Patients with a current diagnosis of asthma.

          -  Further exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordination Dr. Robert Voves, 8330 Feldbach</name>
      <address>
        <city>Feldbach</city>
        <zip>8330</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH d. Elisabethinen Linz</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus Universitetshospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Silkeborg</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jorvin sairaala</name>
      <address>
        <city>Espoo</city>
        <zip>FI-02740</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HYKS Keuhkosairauksien</name>
      <address>
        <city>Helsinki</city>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TAYS, Keuhkotautien poliklinikka</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS, Keuhkosairauksien klinikka, Turku</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Terveystalo Pulssi, Turku</name>
      <address>
        <city>Turku</city>
        <zip>FI-20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CLI du Parc, Pneumo, Castelnau le Lez</name>
      <address>
        <city>Castelnau Le Lez</city>
        <zip>34170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Pigearias B., Pneumo, Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Dupouy J, Pneumo, Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30900</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HOP Maison Blanche</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>INS A.Tzanck,Pneumo,St Laurent du Var</name>
      <address>
        <city>Saint Laurent du Var</city>
        <zip>06721</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CAB Lejay D, MG, Vieux Condé</name>
      <address>
        <city>Vieux Condé</city>
        <zip>59690</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. Clinic of Respiratory and Allergic Diseases, Golnik</name>
      <address>
        <city>Golnik</city>
        <zip>4204</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Verboten Kopriva Renata - Private practice, Litija</name>
      <address>
        <city>Litija</city>
        <zip>1270</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arjana Macek d.o.o.</name>
      <address>
        <city>Ljubljana</city>
        <zip>1000</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Slovenia</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>February 12, 2016</study_first_submitted>
  <study_first_submitted_qc>February 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>December 7, 2017</results_first_submitted>
  <results_first_submitted_qc>December 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2018</results_first_posted>
  <last_update_submitted>December 7, 2017</last_update_submitted>
  <last_update_submitted_qc>December 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Olodaterol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Definition: Open-Label Treated Set (OLTS): This patient set includes all patients who signed the informed consent and were dispensed open-label study medication during the run-in period prior to randomisation and were documented to have taken any dose of this medication.</recruitment_details>
      <pre_assignment_details>Definition: Randomised Set (RS): This patient set is nested within the OLTS and includes all patients who signed the informed consent form and were also randomised, regardless of whether the patient was treated with study medication or not.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>T+O 5/5</title>
          <description>The subjects were administered Tiotropium (T) + Olodaterol (O) Fixed Dose Combination (FDC) solution for inhalation 2.5 μg/2.5 μg per actuation, 2 inhalations orally once daily via RESPIMAT® inhaler.
Placebo matching Tiotropium solution was administered 2 inhalations once daily via RESPIMAT® inhaler.</description>
        </group>
        <group group_id="P2">
          <title>T 5/O 5</title>
          <description>The subjects were administered Tiotropium solution for inhalation, 2.5 μg per actuation + Olodaterol solution for inhalation, 2.5 μg per actuation as a free combination. Two inhalations were administered once daily (a.m. dosing) via RESPIMAT® inhaler for both Tiotropium and Olodaterol.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set [TS]: This patient set is nested within the RS and includes all patients who were dispensed study medication and were documented to have taken any dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>T+O 5/5</title>
          <description>The subjects were administered Tiotropium (T) + Olodaterol (O) Fixed Dose Combination (FDC) solution for inhalation 2.5 μg/2.5 μg per actuation, 2 inhalations orally once daily via RESPIMAT® inhaler.
Placebo matching Tiotropium solution was administered 2 inhalations once daily via RESPIMAT® inhaler.</description>
        </group>
        <group group_id="B2">
          <title>T 5/O 5</title>
          <description>The subjects were administered Tiotropium solution for inhalation, 2.5 μg per actuation + Olodaterol solution for inhalation, 2.5 μg per actuation as a free combination. Two inhalations were administered once daily (a.m. dosing) via RESPIMAT® inhaler for both Tiotropium and Olodaterol.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="7.1"/>
                    <measurement group_id="B2" value="66.5" spread="6.4"/>
                    <measurement group_id="B3" value="66.5" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Trough Forced Expiratory Volume in 1 Second (FEV1) (in Liter) After 28 Days of Treatment</title>
        <description>This outcome measure presents FEV1 after 28 days of treatment (measurement on Day 29). Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), and was measured at 24 hours (+/- 10 minutes) after trial medication administration at Visit 5.
The FEV1 measurement at Visit 4, which was 24 hours after the last open-label run-in treatment intake and 15 minutes before the first double-blind study drug intake was the baseline measurement.</description>
        <time_frame>Day 29</time_frame>
        <population>Full Analysis Set (FAS): This patient set is nested within the TS and includes patients who had a baseline measurement and at least one post-baseline measurement for the primary endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>T+O 5/5</title>
            <description>The subjects were administered Tiotropium (T) + Olodaterol (O) Fixed Dose Combination (FDC) solution for inhalation 2.5 μg/2.5 μg per actuation, 2 inhalations orally once daily via RESPIMAT® inhaler.
Placebo matching Tiotropium solution was administered 2 inhalations once daily via RESPIMAT® inhaler.</description>
          </group>
          <group group_id="O2">
            <title>T 5/O 5</title>
            <description>The subjects were administered Tiotropium solution for inhalation, 2.5 μg per actuation + Olodaterol solution for inhalation, 2.5 μg per actuation as a free combination. Two inhalations were administered once daily (a.m. dosing) via RESPIMAT® inhaler for both Tiotropium and Olodaterol.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Expiratory Volume in 1 Second (FEV1) (in Liter) After 28 Days of Treatment</title>
          <description>This outcome measure presents FEV1 after 28 days of treatment (measurement on Day 29). Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), and was measured at 24 hours (+/- 10 minutes) after trial medication administration at Visit 5.
The FEV1 measurement at Visit 4, which was 24 hours after the last open-label run-in treatment intake and 15 minutes before the first double-blind study drug intake was the baseline measurement.</description>
          <population>Full Analysis Set (FAS): This patient set is nested within the TS and includes patients who had a baseline measurement and at least one post-baseline measurement for the primary endpoint.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.422" spread="0.016"/>
                    <measurement group_id="O2" value="1.399" spread="0.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary analysis was conducted using an Analysis of Covariance [ANCOVA] model including treatment as fixed categorical effect and baseline as continuous covariate.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of the Tio+Olo FDC versus the Tio/Olo free combination was tested at the one-sided α-level of 0.025 using a non-inferiority margin of 0.1 L.</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.022</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.020</ci_lower_limit>
            <ci_upper_limit>0.067</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Forced Vital Capacity (FVC) (in Liter) After 28 Days of Treatment</title>
        <description>This outcome measure presents trough FVC after 28 days of treatment (measurement on Day 29).
The FVC measurement at Visit 4, which was 24 hours after the last open-label run-in treatment intake and 15 minutes before the first double-blind study drug intake was the baseline measurement for FVC.</description>
        <time_frame>Day 29</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>T+O 5/5</title>
            <description>The subjects were administered Tiotropium (T) + Olodaterol (O) Fixed Dose Combination (FDC) solution for inhalation 2.5 μg/2.5 μg per actuation, 2 inhalations orally once daily via RESPIMAT® inhaler.
Placebo matching Tiotropium solution was administered 2 inhalations once daily via RESPIMAT® inhaler.</description>
          </group>
          <group group_id="O2">
            <title>T 5/O 5</title>
            <description>The subjects were administered Tiotropium solution for inhalation, 2.5 μg per actuation + Olodaterol solution for inhalation, 2.5 μg per actuation as a free combination. Two inhalations were administered once daily (a.m. dosing) via RESPIMAT® inhaler for both Tiotropium and Olodaterol.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Forced Vital Capacity (FVC) (in Liter) After 28 Days of Treatment</title>
          <description>This outcome measure presents trough FVC after 28 days of treatment (measurement on Day 29).
The FVC measurement at Visit 4, which was 24 hours after the last open-label run-in treatment intake and 15 minutes before the first double-blind study drug intake was the baseline measurement for FVC.</description>
          <population>FAS.</population>
          <units>Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.126" spread="0.024"/>
                    <measurement group_id="O2" value="3.121" spread="0.024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary analysis was conducted using an ANCOVA model including treatment as fixed categorical effect and baseline as continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8648</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean</param_type>
            <param_value>0.006</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.034</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.061</ci_lower_limit>
            <ci_upper_limit>0.073</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Obstructive Pulmonary Disease (COPD) Assessment Test™ (CAT) Score on Day 28</title>
        <description>This outcome measure presents COPD assessment test score on Day 28. The COPD Assessment Test™ is a short 8-item questionnaire for assessment and monitoring of COPD health status in routine practice. Its scale is 0-40 (high score = poor health).
The CAT measurement on Visit 4 prior to the first dose of double-blind study drug was the baseline for CAT.</description>
        <time_frame>Day 28</time_frame>
        <population>FAS. One patient in the T 5/O 5 free combination group had missing data for the CAT questionnaire.</population>
        <group_list>
          <group group_id="O1">
            <title>T+O 5/5</title>
            <description>The subjects were administered Tiotropium (T) + Olodaterol (O) Fixed Dose Combination (FDC) solution for inhalation 2.5 μg/2.5 μg per actuation, 2 inhalations orally once daily via RESPIMAT® inhaler.
Placebo matching Tiotropium solution was administered 2 inhalations once daily via RESPIMAT® inhaler.</description>
          </group>
          <group group_id="O2">
            <title>T 5/O 5</title>
            <description>The subjects were administered Tiotropium solution for inhalation, 2.5 μg per actuation + Olodaterol solution for inhalation, 2.5 μg per actuation as a free combination. Two inhalations were administered once daily (a.m. dosing) via RESPIMAT® inhaler for both Tiotropium and Olodaterol.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Obstructive Pulmonary Disease (COPD) Assessment Test™ (CAT) Score on Day 28</title>
          <description>This outcome measure presents COPD assessment test score on Day 28. The COPD Assessment Test™ is a short 8-item questionnaire for assessment and monitoring of COPD health status in routine practice. Its scale is 0-40 (high score = poor health).
The CAT measurement on Visit 4 prior to the first dose of double-blind study drug was the baseline for CAT.</description>
          <population>FAS. One patient in the T 5/O 5 free combination group had missing data for the CAT questionnaire.</population>
          <units>Score on scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.423" spread="0.377"/>
                    <measurement group_id="O2" value="15.750" spread="0.379"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The secondary analysis was conducted using an ANCOVA model including treatment as fixed categorical effect and baseline as continuous covariate.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5420</p_value>
            <method>ANCOVA</method>
            <param_type>Adjusted mean</param_type>
            <param_value>-0.327</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.536</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.384</ci_lower_limit>
            <ci_upper_limit>0.729</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 28 days after last drug administration, up to 49 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>T+O 5/5</title>
          <description>The subjects were administered Tiotropium (T) + Olodaterol (O) Fixed Dose Combination (FDC) solution for inhalation 2.5 μg/2.5 μg per actuation, 2 inhalations orally once daily via RESPIMAT® inhaler.
Placebo matching Tiotropium solution was administered 2 inhalations once daily via RESPIMAT® inhaler.</description>
        </group>
        <group group_id="E2">
          <title>T 5/O 5</title>
          <description>The subjects were administered Tiotropium solution for inhalation, 2.5 μg per actuation + Olodaterol solution for inhalation, 2.5 μg per actuation as a free combination. Two inhalations were administered once daily (a.m. dosing) via RESPIMAT® inhaler for both Tiotropium and Olodaterol.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>The total number of subjects who were administered T+O 5/5 or T 5/O 5.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="221"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI’s intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

